Countervail Corporation


US Patent application submitted for novel OP Exposure Diagnostic Test.

In June of 2015, Countervail submitted a provisional patent application for a unique diagnostic test design for the detection and quantitation of the degree of exposure to organophosphorus (OP) (e.g., nerve agents and pesticides) toxins. This unique field based design allows for rapid screening for exposure followed by quantitation in a single test and eliminates the need for a baseline result for determination of accurate quantitative results.

Rapid availability to field based medical personnel of the degree of OP exposure to these toxins will aid in guiding antidotal therapeutic regimens.